Rocket Secures $150M Hercules Credit Facility, Issues 1.76M Warrants at $2.99
RCKT is trading near its 52-week low of $2.46 (1.6% above the low).
Summary
Rocket Pharmaceuticals closed a $150M credit facility with Hercules Capital, drawing $35M upfront and issuing 1.76M warrants at $2.99. The financing extends cash runway into Q3 2028 and funds the pivotal Danon disease trial.
Key Events · Financing and Capital Events · RCKT
-
$150M Credit Facility Closed
Rocket entered a senior secured term loan agreement with Hercules Capital for up to $150M across five tranches. $35M Tranche 1-A was funded on September 30, 2026.
-
Warrants Issued at $2.99 Strike
Lenders received warrants for 1,755,853 shares at $2.99 exercise price. 409,699 warrants are exercisable after the initial $35M draw; full vesting requires drawing the entire $150M.
-
Cash Runway Extended to Q3 2028
Combined with $283.7M cash as of June 30, 2026, the initial $35M draw funds operations into Q3 2028. Additional draws could extend runway into 2029.
-
Minimum Cash Covenant
Borrower must maintain qualified cash equal to 35-75% of outstanding principal, tested from July 2027. Covenant is suspended if market cap exceeds $600M.
Analysis · RCKT · Life Sciences
A $150 million senior secured term loan facility with Hercules Capital has been closed, with $35 million drawn upfront. The deal includes warrants to purchase 1,755,853 shares at $2.99 — a strike price above the current $2.50 stock price, meaning the warrants are out-of-the-money today. The facility extends Rocket's cash runway into Q3 2028, removing near-term financing risk for the pivotal Danon disease program. The minimum cash covenant (35-75% of outstanding principal) is suspended if market cap exceeds $600 million, giving Rocket flexibility if its gene therapy data drives a re-rating. This is a survival-positive financing for a company trading near its 52-week low, though the warrant overhang and senior secured position on all assets including IP represent real concessions to the lender.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RCKT was trading at $2.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $272.2M. The 52-week trading range was $2.46 to $5.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.